Latest From FibroGen Inc.
With a long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new approvals such as roxadustat.
Though the policy environment can be 'uncertain,' AstraZeneca has 'good grasp' on how the anemia drug for patients with chronic kidney disease will be covered under the Medicare end-stage renal disease bundled payment system, senior VP for market access Rick Suarez says.
Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.
Highlights of year-end application submissions including candidates from AstraZeneca, BioMarin, Lilly, MorphoSys, and Seattle Genetics.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Hepatic (Liver)
- Musculoskeletal & Connective Tissue Disorders
- Renal System
- North America
- Parent & Subsidiaries
- FibroGen Inc.
- Senior Management
Enrique Conterno, CEO
Pat Cotroneo, VP, Fin. & CFO
David M Dimmick, MD, VP, Quality
R. Wayne Frost, VP, RA
Elias Kouchakji, MD, VP, Clinical Dev and Drug Safety
AI Lin, MD, PhD, VP, Drug Dev.
Peony K Yu, CMO
- Contact Info
Phone: (415) 978-1200
409 Illinois St.
San Francisco, CA 94158
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.